Rare Xq23 Microdeletion: Lissencephaly, Agenesis of the Corpus Callosum, and Epilepsy Case Report

A rare Xq23 microdeletion involving the DCX and PAK3 genes has been documented in medical literature, presenting with lissencephaly, agenesis of the corpus callosum, and intractable epilepsy, according to a case report published in the journal Cureus. The finding provides clinicians with new documentation on how specific genetic deletions on the X chromosome intersect with severe structural brain malformations and treatment-resistant seizures.

Genetic Findings and Structural Brain Anomalies

The case report outlines the clinical presentation of a patient carrying an Xq23 microdeletion. This specific genetic span encompasses both the DCX gene, known for its role in neuronal migration, and the PAK3 gene, which is associated with cognitive function and synaptic plasticity. According to the Cureus study, the deletion results in profound developmental implications, notably lissencephaly—characterized by a smooth brain surface lacking normal folds—and agenesis of the corpus callosum, where the nerve bundle connecting the brain’s hemispheres fails to develop.

Mutations or deletions involving the DCX gene frequently disrupt proper neuronal positioning during embryonic development. When paired with alterations in PAK3, the structural and neurological consequences compound significantly. The study details how these overlapping genetic losses manifest in complex neurodevelopmental phenotypes that require intensive medical management.

Clinical Management of Intractable Epilepsy

A primary clinical challenge highlighted in the case report is the presence of intractable epilepsy. Patients presenting with this form of seizure disorder experience frequent seizures that do not respond adequately to standard anti-seizure medications. The structural brain abnormalities identified in the case, including lissencephaly, provide an anatomical substrate that often drives refractory seizure activity.

Medical teams managing cases involving Xq23 microdeletions must navigate complex therapeutic landscapes. Because standard pharmacological interventions frequently fail to control intractable epilepsy in the presence of major migrational disorders, patient care typically centers on multidisciplinary supportive strategies and palliative seizure management. The Cureus report contributes to the broader medical understanding of rare chromosomal microdeletions by detailing the exact phenotypic expression tied to the simultaneous loss of DCX and PAK3.